Share this to:

Support & Insight for the Autumn of Life

Advantages of Namzaric for Dementia


Namazaric for dementia comes in a convenient, extended-release capsule. It conveniently combines today’s 2 most popular drugs for Alzheimer’s. Learn about easy-to-manage Namazaric.

Namzaric is a fixed-dose combination (FDC) of Namenda (known generically as memantine hydrochloride) and Aricept (known generically as donepezil hydrochloride). Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer’s type.

Continued below Namazaric’s video ad…


The benefits of Namzaric over current treatments include:

  1. Extended release formulation: This means that the medication is in a capsule that releases it to the body slowly, over the course of the day. This can sometimes make it easier for the body to absorb, with fewer side effects, and with more consistent results throughout the day.
  2. One pill: The pill regimen for seniors is often difficult and complex. The fewer pills a person needs to remember to take, and the fewer times per day they need to do so, the better.
  3. Capsule can be opened: Namzaric comes in an easy-to-open capsule, making it simple to sprinkle the medication over or into food.

Aricept + Namenda (Donepezil+Memantine)

Memantine is the generic active ingredient in the currently marketed NAMENDA®, which is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Donepezil is the active ingredient in ARICEPT®, which is indicated for the treatment of mild to severe dementia of the Alzheimer’s type.

Brand Name Generic Name Type
Aricept donepezil AChEI (Acetylcholinesterase Inhibitor)
Namenda memantine NMDA Receptor Antagonist

“Namzaric combines, in one capsule, two complementary therapeutic agents which are often co-prescribed as approximately 70% of Namenda XR patients are also on AChEI therapy. Both Namenda XR and donepezil have proven efficacy and safety, for the treatment of moderate to severe Alzheimer’s disease. Additionally, data has shown that combination therapy with Namenda XR and an AChEI demonstrated greater improvement in cognition and global function verses an AChEI alone,” said David Nicholson, Actavis Senior Vice President, Global Brands R&D. “Along with our partner Adamas, we are proud that this important therapy will provide a convenient and innovative treatment option for Alzheimer’s patients and caregivers that reduces the number of capsules they are required to take each day for the treatment of this devastating disease.”

“We are excited about the approval of Namzaric — the first fixed-dose combination of extended-release memantine and donepezil — and look forward to its launch by Actavis in 2015,” said Gregory T. Went, Ph.D., Chairman and CEO of Adamas Pharmaceuticals, Inc. “Namzaric is also the first FDA-approved FDC product to emerge from Adamas’ platform for modifying the pharmacokinetic profiles of approved drugs, and we look forward to developing additional new treatments for individuals with serious neurological CNS disorders.”

Namzaric = Memantine + Donepezil

Namzaric, formerly known as MDX-8704, is a once-daily oral capsule for patients currently taking memantine (10 mg twice daily or 28 mg extended-release once-daily) and donepezil 10 mg. In addition, the capsules can be opened to allow the contents to be sprinkled on food to facilitate dosing for patients who may have difficulty swallowing.

“When determining therapies for my patients in the moderate to severe stages of Alzheimer’s disease, I consider the therapy’s effectiveness, safety profile and its ease of administration. The FDA’s approval of Namzaric offers a new therapeutic option that provides patients a fixed-dose combination of two treatments often prescribed together, in one capsule,” said Gustavo Alva, MD, Neuropsychiatrist and Medical Director at ATP Clinical Research in Costa Mesa, CA and volunteer faculty member at University of California, Irvine.

Namzaric is available in two dosage strengths, 28/10 mg (memantine extended release/donepezil) and 14/10mg (memantine extended release/donepezil) for patients with severe renal impairment. Actavis and Adamas collaborated on the development of the fixed-dose combination and Actavis will have exclusive U.S. commercialization rights, while Adamas will retain exclusive commercialization rights outside of the U.S. Actavis expects to launch Namzaric in the U.S. in the second quarter of 2015.

Results from the Clinical Trials

The efficacy and safety of the coadministration of memantine HCl extended release and acetylcholinesterase inhibitors (AChEIs), including donepezil HCl, was based on the results of a randomized, double-blind, placebo-controlled trial of 677 outpatients on a stable dose of AChEIs. The clinical study was not conducted with Namazaric; however, bioequivalence of Namazaric with coadministered memantine HCl extended release and donepezil HCl was demonstrated. Approximately 68% of the patients randomized to receive either memantine HCl extended release 28 mg or placebo were taking donepezil as the AchEI at Baseline and throughout the study. The results of this study, demonstrated statistically significant improvement in cognition and global function for patients treated with NAMENDA XR 28 mg plus an AChEI compared to placebo plus an AChEI.

The most commonly observed adverse reactions seen with memantine hydrochloride extended-release in patients with moderate to severe Alzheimer’s disease, defined as those occurring at a frequency of at least 5% in the memantine hydrochloride extended-release group and at a higher frequency than placebo, were headache, diarrhea, and dizziness.

Help your loved one receive a 30-day trial supply of NAMZARIC at $0 out-of-pocket cost with Namzaric’s Trial Offer. Click here.


About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company achieves this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone or in fixed-dose combination products. Adamas is currently developing its lead wholly-owned product candidate, ADS-5102, for a complication of Parkinson’s disease known as levodopa-induced dyskinesia, or LID, and is evaluating other potential indications. The company’s portfolio also includes two approved products developed with Forest. The first is a fixed-dose combination product, Namzaric, and the second is a controlled-release product, Namenda XR®. Forest markets both products in the United States under an exclusive license from Adamas. For more information, please visit

About Actavis
Actavis plc (NYSE:ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

For more information, visit Actavis’ website at

SOURCE: Actavis plc

Notify of

Inline Feedbacks
View all comments
December 27, 2014 2:54 am

It will be interesting to see if patients are able to get this. When Namenda went to an XR form, pharmacies were unable to get adequate supplies. It must be heartbreaking for people to have hope for the latest and greatest but then not be able to get their hands on any.
Reply to  Judy
December 28, 2014 4:13 am

Judy, while you are right in bringing up the Namenda XR supply problem, it is important to keep in mind that t was an exception, rather than the rule. That i why the courts stepped in to put a stop to that shortage. Read more about it at:

Judge Ends Shortage of Namenda-IR for Alzheimer's

December 29, 2014 11:58 am

Are thEre plans to release this medication in the UK? Kath

October 9, 2016 6:18 pm

The well-being benefits of increasing your personal garden area unit several. All folks perceive that veggies area unit nice for you in person, significantly the greens.

January 25, 2019 8:09 pm

It is pricey. Copay is $500 for 90 day supply but seems to help some & is more easily managed than 3 separate pills/day.

B. Berger

B. Berger

Visit Our Pages On:


This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor


Common Alzheimer's Medications Slow Cognitive Decline
Swedish researchers find that cholinesterase inhibitors provide cognitive benefits and reduce mortality for up to fiv...
Lilly's Donanemab: The 3rd New Alzheimer's Drug
Now, a third new Alzheimer's drug expected to be approved by the Food and Drug Administration (FDA),. The field of ne...
Leqembi Medication for Alzheimer's (Generic: Lecanemab)
Alzheimer's Drug Leqembi Gets Full FDA and MEDICARE Approval
First drug to modestly slow Alzheimer's cognitive decline, based on 1,800 patients.
Would love your thoughts, please comment.x
News, Treatments, Care Tips

Subscribe To The Weekly Newsletter

videos & articles on Research & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter